Renal involvement in chronic lymphocytic leukemia

被引:32
作者
Wanchoo, Rimda [1 ]
Ramirez, Carolina Bernabe [2 ]
Barrientos, Jacqueline [2 ,3 ]
Jhaveri, Kenar D. [1 ]
机构
[1] Zucker Sch Med Hofstra Northwell, Div Kidney Dis & Hypertens, Great Neck, NY 11021 USA
[2] Zucker Sch Med Hofstra Northwell, Div Hematol & Oncol, Lake Success, NY USA
[3] CLL Res & Treatment Program, Lake Success, NY USA
关键词
AKI; CLL; infiltration; leukemia; onconephrology; paraproteinemia; venetoclax; TUMOR LYSIS SYNDROME; B-CELL LYMPHOCYTOSIS; LIGHT-CHAIN; OPEN-LABEL; LYMPHOPROLIFERATIVE DISORDERS; MONOCLONAL GAMMOPATHY; PSEUDOHYPERKALEMIA; HYPERCALCEMIA; RITUXIMAB; PATIENT;
D O I
10.1093/ckj/sfy026
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe. Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment. Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the monoclonal antibody obinutuzumab are important nephrotoxicities associated with these agents. Here we review the various forms of kidney diseases associated with CLL and its therapies.
引用
收藏
页码:670 / 680
页数:11
相关论文
共 50 条
[41]   Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy [J].
Roeker, Lindsey E. ;
Thompson, Meghan ;
Mato, Anthony R. .
DRUGS, 2022, 82 (02) :133-143
[42]   Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm [J].
Sengar, Manju ;
Jain, Hasmukh ;
Rajendra, Akhil ;
Rengaraj, Karthik ;
Thorat, Jayashree .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (03) :168-176
[43]   Sequential and combination treatments with novel agents in chronic lymphocytic leukemia [J].
Fuerstenau, Moritz ;
Hallek, Michael ;
Eichhorst, Barbara .
HAEMATOLOGICA, 2019, 104 (11) :2144-2154
[44]   Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review [J].
Islam, Prioty .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) :1259-1273
[45]   Novel therapy concepts for chronic lymphocytic leukemia [J].
Eichhorst, Barbara ;
Hallek, Michael .
ONKOLOGE, 2016, 22 (04) :283-292
[46]   An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia [J].
Salvaris, Ross ;
Opat, Stephen .
FUTURE ONCOLOGY, 2020, 17 (04) :371-387
[47]   Treatment of chronic lymphocytic leukemia in older adults [J].
Rowswell-Turner, Rachael B. ;
Barr, Paul M. .
JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (05) :315-319
[48]   Management of relapsed/refractory chronic lymphocytic leukemia [J].
Tomowiak, Cecile .
HEMATOLOGIE, 2024, 30 :19-27
[49]   Primer on Chronic Lymphocytic Leukemia: Part II [J].
Hughes, Mitchell E. ;
Gill, Jennifer .
JNP-JOURNAL FOR NURSE PRACTITIONERS, 2018, 14 (04) :309-+
[50]   Management of relapsed/refractory Chronic Lymphocytic Leukemia [J].
Woyach, Jennifer A. .
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 :S11-S18